{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:19:40Z","timestamp":1793110780101,"version":"4.5.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Adverse Drug Reactions (ADR) are one of the common causes of hospital\nadmissions and pose a significant clinical and economic burden on the healthcare system.\nThe Adverse Drug Reaction Monitoring Centre (AMC) in JIPMER functioning under the Pharmacovigilance\nProgramme of India (PvPI) plays a vital role in ensuring medication safety by\nroutinely detecting and monitoring ADRs. Hence, this study aimed to assess the characteristics\nof ADR reported from 2010 to 2020 in AMC JIPMER and to detect signals, if any.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Materials and Methods:<\/jats:title>\n<jats:p>A total of 6007 ADR reports with a single suspect drug were included\nfor analysis from 2010 to 2020. The characteristics of these reports, including patient\u2019s age and\ngender, Number and percentage of ADRs, the causality of ADR using WHO UMC (World\nHealth Organization-Uppsala Monitoring Centre) scale, the seriousness of the ADR, and outcome\nwere collected from the ADR reports. MedDRA (Medical Dictionary for Regulatory Activities)\nPreferred Terms (PT) were used to classify adverse drug reactions. Causality analysis\nusing the Naranjo Algorithm and Preventability using Modified Schumock and Thornton criteria\nwere performed for the ADRs. The number and percentage of severe ADRs were analyzed. The\nSystem Organ class of all the ADRs was enumerated. ADRs not mentioned in the US FDA\n(United States Food and Drug Administration) product label (unlabelled reactions) were documented.\nUnlabeled reactions with \u22653 ADR reports were included for signal detection by disproportionality\nanalysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To study the characteristics of Adverse Drug Reactions (ADR) reported to a regional\nADR monitoring center from 2010 to 2020 and to detect signals of disproportionate reporting\n(SDRs) if any from the reported ADRs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Antineoplastic drugs, followed by antimicrobials, anticonvulsants, Anti snake venom,\nand NSAID were the most common drugs implicated in ADRs. Skin and subcutaneous tissue\ndisorders were the most common System Organ Class (SOC) involved in the ADRs. Among the\n6007 reports, 19.2% were serious ADRs. Most of the ADR reports were of possible causality\nfollowed by probable and certain as per WHO UMC and Naranjo causality scales. Only ten\nADRs were preventable and one reaction (Tamoxifen-induced neuropathy) was eligible for signal\ndetection. Disproportionality analysis using a 2x2 contingency table showed insignificant\nsignal detection using the Reporting Odds Ratio (ROR) and Proportional Reporting Ratio\n(PRR).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Analysis of ADRs from an ADR Monitoring center functioning in a tertiary care\nhospital shows antineoplastic drugs to be the most common drugs associated with adverse drug\nreactions, with rash being the most common adverse effect. The majority of the ADRs were not\npreventable. No Signals of Disproportionate Reporting (SDR) were detected in our study.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115748863317987241015034413","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T11:13:56Z","timestamp":1729682036000},"page":"349-360","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Retrospective Observational Study of Adverse Drug Reactions (ADR) Reported to ADR Monitoring Centre from 2010 to 2020"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0881-3877","authenticated-orcid":true,"given":"Akila","family":"Srinivasan","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Mahatma Gandhi Medical College and Research Institute (MGMCRI), Sri Balaji\nVidyapeeth, Pondicherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7948-7821","authenticated-orcid":true,"given":"Sandhiya","family":"Selvarajan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, JIPMER, Pondicherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7871-1038","authenticated-orcid":true,"given":"Santhosh","family":"Shivabasappa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, JIPMER, Pondicherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunmozhy","family":"S.","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Associate, Department of Clinical Pharmacology, JIPMER, Pondicherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748863317987241015034413","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/235524\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748863317987241015034413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T04:33:10Z","timestamp":1747110790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/235524\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115748863317987241015034413","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-04-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}